Evidence map›Paper›PMID 33681764›Full record

ArticleNeuro-oncology advances

The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.

Alex Shimura Yamashita, Marina da Costa Rosa, Vittorio Stumpo, Rana Rais, Barbara S Slusher, Gregory J Riggins

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Targeting the Glutaminolysis Pathway in Glaucoma-Associated Fibrosis.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Targeting glutamine metabolism as a potential target for cancer treatment.Journal of experimental & clinical cancer research : CR · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alex Shimura YamashitaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marina da Costa RosaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Vittorio StumpoDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rana RaisJohns Hopkins Drug Discovery, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gregory J RigginsDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Optimizing demethylating therapy for IDH1 Mutant Malignant GliomasR01CA190223 · NCI · JOHNS HOPKINS UNIVERSITY · PI RIGGINS, GREGORY JOSEPH · 2015 to 2024
$3.4M
Cell-targeted glutamine antagonists as a novel therapy for lymphomaR01CA229451 · NCI · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH · 2018 to 2022
$2.3M
Targeting Tumor Metabolism as a Means of Enhancing ImmunotherapyR01CA226765 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEONE, ROBERT DAVID · 2019 to 2023
$1.9M
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastomaR01NS103927 · NINDS · JOHNS HOPKINS UNIVERSITY · PI RAABE, ERIC HUTTON, SLUSHER, BARBARA STAUCH · 2018 to 2021
$1.6M
NCI NIH HHS R01 CA190223NCI NIH HHS R01 CA226765NCI NIH HHS R01 CA229451NINDS NIH HHS R01 NS103927
6 · The paper itself

Abstract

backgroundMetabolic reprogramming is a common feature in cancer, and it is critical to facilitate cancer cell growth. MATERIAL AND

methodsWe performed cell growth, cell cycle, and protein expression in glutamine deprived or

resultsGlutamine deprivation and

conclusionTargeting glutamine metabolism with JHU-083 showed efficacy in preclinical models of

Indexed as

cell cyclegliomaglutamine metabolismIDH mutationmTOR signaling

Identifiers

PMID33681764
PMCPMC7920530
OpenAlexW3094719342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.